Abstract: A method for the production of substituted aromatic aldehydes or ketones and optionally substituted heteroaromatic aldehydes or ketones of formula (I) by reacting a compound of formula (II) in a suitable solvent in the presence of a carbonyl compound of formula (III), optionally in the presence of oxygen at a normal pressure or high temperature and at temperatures of 5-200° C.
Type:
Application
Filed:
September 20, 2002
Publication date:
March 6, 2003
Inventors:
Wolfram Hendel, Ferdinand Heu, Peter Poechlauer, Berthold Winkler
Abstract: It is an objective to produce intermediates of optically active beta-3 adrenaline receptor agonists from readily available raw materials in a safe, efficient and industrially advantageous manner. A substituted acetylpyridine derivative represented by the general formula (9) is reduced by enantioselective reduction to produce an optically active hydroxyethyl derivative represented by the general formula (10) (wherein * represents an asymmetric carbon atom), and it is further derivatized to an intermediate of an optically active beta-3 adrenaline receptor agonist, such as an optically active dihydroxyethylpyridine derivative represented by the general formula (14) or an optically active oxirane derivative represented by the general formula (16).
Abstract:
Compounds of structure (1) are obtained by reduction of compounds of the structures
Compounds of structure (1), especially where Z is a hydrogen atom or a 3,4-methylenedioxyphenyl group, are important intermediates for inter alia paroxetine.
Type:
Grant
Filed:
May 29, 1998
Date of Patent:
December 3, 2002
Assignee:
SmithKline Beecham plc
Inventors:
Victor Withold Jacewicz, Marvin Sungwhan Yu, Evgeny Shapiro
Abstract:
The present invention is concerned with new pyridine double esters of formula (I), their acids, and pharmaceutically acceptable salts. These compounds can be obtained by oxydation of the corresponding 1,4-dihydropyridines, and they are useful as cardioprotective agents in pharmaceutical compositions.
Type:
Grant
Filed:
April 7, 2000
Date of Patent:
November 19, 2002
Assignee:
Cermol S.A.
Inventors:
Carlos Sunkel Letelier, Miguel Fau De Casa-Juana Munoz, Julio Alvarez-Builla Gomez, José M. Minguez Ortega, Pierre Statkow, Danielle Straumann, Shyam S. Chatterjee
Abstract: Invented is an improved process for preparing aromatic ring-fused cyclopentane derivatives. Preferred compounds prepared by this invention are indane carboxylates and cyclopentano[b]pyridine derivatives. The most preferred compounds prepared by this inventino are (+)(1S, 2R, 3S)-3-[2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof and (+)(1S, 2R, 3S)-3-[(2-carboxymethoxy-4-methoxyphenyl)-1- (3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof. Also invented are novel intermediates useful in preparing these compounds.
Type:
Grant
Filed:
September 10, 2001
Date of Patent:
November 12, 2002
Assignee:
SmithKline Beecham Corporation
Inventors:
Yemane Woldeselassie Andemichael, Neil Howard Baine, William Morrow Clark, Conrad John Kowalski, Michael Anthony McGuire, Robert John Mills
Abstract: The present invention describes an improved process for the preparation of 2-chloro-5-methylpyridine-3-carbaldehyde from N-benzyl-N-(1-Propenyl)acetamide using diphosgene and dimethylformamide or triphosgene and dimethylformamide (Vilsmeyer reagent) in 92% yield against reported 12% yield. The present invention has the advantage of using diphosgene and triphosgene instead of toxic phosgene gas and phosphorousoxytrichloride, thereby avoiding the formation of phosphorous salt.
Type:
Grant
Filed:
March 18, 2002
Date of Patent:
November 12, 2002
Assignee:
Council of Scientific and Industrial Research
Abstract: An amlodipine derivative having the following formula is useful, either alone or in combination with amlodipine, as a pharmaceutical in treating angina and hypertension.
Type:
Application
Filed:
August 27, 2001
Publication date:
September 12, 2002
Inventors:
Jacobus M. Lemmens, Theodorus H. A. Peters, Franciscus B.G. Benneker
Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1
Type:
Application
Filed:
January 31, 2002
Publication date:
August 15, 2002
Applicant:
Pfizer Inc.
Inventors:
Thomas Victor Magee, Anthony Marfat, Robert James Chambers
Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.
Type:
Grant
Filed:
September 5, 2000
Date of Patent:
August 6, 2002
Assignee:
Eli Lilly and Company
Inventors:
Sean P. Hollinshead, Michael A. Staszak, John S. Ward, Joseph W. Wilson, Bret E. Huff, Philip F. Hughes, Jose S. Mendoza, Charles H. Mitch
Abstract: The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent.
Abstract: Neuroprotective agents are disclosed having the following structure:
wherein R1, R2, R3, R4 and R5 are as defined herein. Such compounds have utility in the treatment of conditions which benefit from administration of neuroprotective agents generally, including treatment of central and peripheral nervous condition as well as for promoting nerve cell differentiation. Methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more of the compounds of this invention.
Type:
Grant
Filed:
November 27, 2000
Date of Patent:
June 4, 2002
Assignee:
Nippon Kayaku Co., Ltd.
Inventors:
Moorthy S. S. Palanki, Shripad S. Bhagwat, Hiroshi Sato, Paul E. Erdman, Mary Doubleday
Abstract: The present invention is concerned with pharmaceutical compositions comprising a mixture of amlodipine enantiomers, which compositions have both anti-hypertensive and additional cardiovascular properties derived respectively from their calcium channel-blocking activity and their ability to release vascular nitric oxide (NO).
Type:
Application
Filed:
August 15, 2001
Publication date:
April 18, 2002
Inventors:
Suresh Babubhai Chahwala, Michael George Dodd, Michael John Humphrey
Abstract: The use of hydroxyphenyl-1,3-propanediones of formula:
wherein
R1 and R2 are each independently of the other hydrogen, C1-C12alkyl, C1-C12alkoxy, trifluoro-C1-C3alkyl, phenyl or halogen;
R3 is a 5- or 6-membered heteroaromatic radical; thiophenyl; or a radical of formula:
R4, R5, R6 and R7 are each independently of the other hydrogen, halogen, C1-C12alkyl, C1-C12alkoxy, carboxy or trifluoro-C1-C3alkyl;
in the antimicrobial treatment of surfaces, is described.
The compounds exhibit a pronounced action against pathogenic gram-positive and gram-negative bacteria, and also against yeasts and molds.
Type:
Grant
Filed:
August 1, 2000
Date of Patent:
February 12, 2002
Assignee:
Ciba Specialty Chemicals Corporation
Inventors:
Werner Hölzl, Wolfgang Haap, Dietmar Ochs, Karin Puchtler, Marcel Schnyder
Abstract:
The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R1 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C4-C20 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C1-C4 alkyl, hydroxyalkyl or alkoxy, hydroxy, halogen, trifluoromethyl, cyano, carboxamido, sulfamoyl, nitro, amino, ca
Abstract: Compounds of the formula
where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
Type:
Grant
Filed:
December 11, 2000
Date of Patent:
February 5, 2002
Assignee:
Allergan Sales, Inc.
Inventors:
Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Yuan Lin, Roshantha A. Chandraratna
Abstract: The invention relates to a process for preparing substituted pyridines in a simple and cost-effective manner in good yields by reacting substituted 1,4-dihydropyridines with methyl nitrite in the presence of an acid that contains less than 20% by weight of oxidizing components.
Type:
Application
Filed:
June 4, 2001
Publication date:
January 3, 2002
Inventors:
Norbert Lui, Hans Panskus, Albert Schnatterer
Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1.
Abstract: The present invention relates to substituted indane or dihydroindole compounds of Formula (I)
wherein A is an indole. These compounds have high affinity for D4 receptors.
Type:
Grant
Filed:
June 21, 1999
Date of Patent:
July 17, 2001
Assignee:
H. Lundbeck A/S
Inventors:
Jens Kristian Perregaard, Benny Bang-Andersen, Henrik Pedersen, Ivan Mikkelsen, Robert Dancer
Abstract: Acylsulfamoylbenzamides of the formula I and crop protection compositions comprising them are described. In this formula I, R1, R2, R3, R4 and R5 are various organic radicals and X is CH or N.
Type:
Grant
Filed:
September 25, 1998
Date of Patent:
June 26, 2001
Assignee:
Hoechst Schering AgrEvo GmbH
Inventors:
Frank Ziemer, Lothar Willms, Thomas Auler, Hermann Bieringer, Christopher Rosinger
Abstract: The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
Type:
Application
Filed:
December 26, 2000
Publication date:
June 7, 2001
Applicant:
AstraZeneca UK Limited
Inventors:
Andrew Baxter, Thomas Mcinally, Michael Mortimore, David Cladingooel
Abstract: The present invention provides dihalopropene compounds of the general formula:
wherein R1 is C1-C10 alkyl or the like; L is C(═O)NH or the like; R2, R3 and R4 are independently halogen or the like; R5, R6 and R7 are independently hydrogen or the like; m is an integer of 0 to 4; n is an integer of 0 to 2; X is chlorine or the like; Y is oxygen or the like; and Z is oxygen or the like, which have excellent insecticidal activity so that they are satisfactorily effective for the control of noxious insects.
Abstract: N,N-disubstituted formamides, wherein the substituents are selected to provide formamides which have low volatility, are useful as halogenation catalysts. Such catalysts are generally less hazardous to use than typical formamide halogenation catalysts because toxic catalyst by-products are also less volatile. Methods for using such catalysts are provided.
Type:
Grant
Filed:
May 15, 2000
Date of Patent:
March 27, 2001
Assignee:
Rohm and Haas Company
Inventors:
Deborah Diane Graves, Thomas Duncan Rose, David James Swank, Charles Chao Wu
Abstract: A poly(oxyalkylene)pyridyl or piperidyl ester having the formula: ##STR1## or a fuel-soluble salt thereof; wherein A is a nitrogen-containing ring selected from the group consisting of 3-pyridyl, 4-pyridyl, 3-piperidyl and 4-piperidyl; R.sub.1 and R.sub.2 are independently hydrogen or lower alkyl having 1 to about 6 carbon atoms and each R.sub.1 and R.sub.2 is independently selected in each --O--CHR.sub.1 --CHR.sub.2 -- unit; R.sub.3 is hydrogen, alkyl having 1 to about 100 carbon atoms, phenyl, aralkyl having about 7 to about 100 carbon atoms or alkaryl having about 7 to about 100 carbon atoms; x is an integer from 0 to 4; and n is an integer from about 5 to about 100.The poly(oxyalkylene)pyridyl and piperidyl esters of the present invention are useful as fuel additives for the prevention and control of engine deposits.
Abstract: The present invention relates to novel tocotrienols and tocotrienol-like compounds displaying biological activity. The tocotrienols and tocotrienol-like compounds of this invention may be conveniently obtained from biological sources or by chemical synthesis and may be used in pharmaceutical compositions, foodstuffs and dietary supplements. This invention also relates to the use of tocotrienols, tocotrienol-like compounds, and mixtures thereof, as hypocholesterolemic, antithrombotic, antioxidizing, antiatherogenic, antiinflammatory and immunoregulatory agents, or as agents useful to decrease lipoprotein (a) concentration in the blood or to increase feed conversion efficiency.
Type:
Grant
Filed:
October 28, 1998
Date of Patent:
November 7, 2000
Assignee:
Lipogenics, Inc.
Inventors:
Ronald H. Lane, Asaf A. Qureshi, Winston A. Salser
Abstract: Compounds with fungicidal properties having formula I ##STR1## where m and n are 0 or 1 provided that m+n is 1; X is hydrogen, halo, (C.sub.1 -C.sub.4)alkyl, or (C.sub.1 -C.sub.4)alkoxy; R is an optionally-substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, or heterocyclic group; R.sub.1 and R.sub.2 are hydrogen, optionally-substituted alkyl, cycloalkyl, cyano, carboxy alkyl, or aryl; at least one of R.sub.1 and R.sub.2 is hydrogen; and R.sub.3 is alkyl or haloalkyl.
Type:
Grant
Filed:
November 23, 1998
Date of Patent:
September 19, 2000
Assignee:
Rohm and Haas Company
Inventors:
Ronald Ross, Ted Tsutomo Fujimoto, Edward Michael Szapacs, Steven Howard Shaber
Abstract: The present application describes 6-membered aromatics of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein D may be CH.sub.2 NH.sub.2 or C(.dbd.NH)NH.sub.2, which are useful as inhibitors of factor Xa.
Type:
Grant
Filed:
June 18, 1998
Date of Patent:
May 9, 2000
Assignee:
Dupont Pharmaceuticals
Inventors:
James Russell Pruitt, Donald Joseph Phillip Pinto, Mimi Lifen Quan, Ruth Richmond Wexler
Abstract: This invention relates to compounds of formula (1): ##STR1## wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands.
Type:
Grant
Filed:
December 9, 1998
Date of Patent:
April 25, 2000
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Rajashekhar Betageri, Pierre L. Beaulieu, Jean-Marie Ferland, Montse Llinas-Brunet, Neil Moss, Usha Patel, John R. Proudfoot, Mario Cardozo
Abstract: A process for the production of 2-chloro-5-chloromethylpyridine of the formula: ##STR1## starting from 6-hydroxynicotinic acid of the formula: ##STR2## In this way 6-hydroxynicotinic acid is reacted with an acid chloride to 6-hydroxynicotinoyl chloride of the formula: ##STR3## The latter is then catalytically hydrogenated with hydrogen to 6-hydroxy-5-hydroxymethylpyridine of the formula: ##STR4## The latter is then catalytically hydrogenated with hydrogen to 2-hydroxy-5-hydroxymethylpyridine of the formula: ##STR5## which is then chlorinated to the end product according to formula I.
Abstract: Compounds, compositions, and methods of use as a pharmaceutical, where the compounds have structure (I), where B is --C(.dbd.O)-- or --CH.sub.2 --O--, C is a direct bond or is a diol residue, a hydroxy-substituted carboxylic acid residue, or a dicarboxylic acid residue, and D is a fatty acid residue or a fatty alcohol residue, where the acid residues or alcohol residues for ester linkages with the corresponding alcohols or acids.
Type:
Grant
Filed:
March 3, 1998
Date of Patent:
January 18, 2000
Inventors:
David Frederick Horrobin, Mehar Manku, Austin McMordie, Philip Knowles, Peter Redden, Andrea Pitt
Abstract: C-terminal compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.
Type:
Grant
Filed:
December 17, 1997
Date of Patent:
November 16, 1999
Assignee:
Abbott Laboratories
Inventors:
Steven K. Davidsen, Alan S. Florjancic, George S. Sheppard, Jamie R. Giesler, Lianhong Xu, Yan Guo, Michael L. Curtin, Michael R. Michaelides, Carol K. Wada, James H. Holms
Abstract: A novel protein adduct is disclosed which is associated with the presence of alcohol liver disease. The adduct is a hybrid product of malondialdehyde and acetaldehyde which act synergistically to bind hepatic proteins. The adduct is highly immunogenic and fluorescent. Methods of detection are also disclosed including monoclonal and polyclonal antibodies.
Type:
Grant
Filed:
April 8, 1997
Date of Patent:
August 17, 1999
Assignee:
The Board of Regents of the University of Nebraska
Inventors:
Geoffrey M. Thiele, Thomas L. McDonald, Dean J. Tuma, Lynell W. Klassen, Michael F. Sorrell
Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
Type:
Grant
Filed:
October 28, 1997
Date of Patent:
July 6, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Mark E. Duggan, George D. Hartman, William F. Hoffman, Nathan C. Ihle
Abstract: Compounds with fungicidal and insecticidal properties having formula I ##STR1## wherein A is N or CH; V is O or NH; m and n are integers 0 and 1 provided that m+n is 1;X is independently selected from hydrogen, halo, (C.sub.1 -C.sub.4)alkyl, and (C.sub.1 -C.sub.4) alkoxy;R is independently selected from, (C.sub.1 -C.sub.12)alkyl, halo(C.sub.1 -C.sub.12)alkyl, (C.sub.2 -C.sub.8) alkenyl, (C.sub.2 -C.sub.8)alkynyl, (C.sub.1 -C.sub.12)alkoxy(C.sub.1 -C.sub.12)alkyl, (C.sub.3 -C.sub.7) cycloalkyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl, aralkyl, and heterocyclic moieties;R is independently selected from (C.sub.1 -C.sub.12)alkyl, halo(C.sub.1 -C.sub.12)alkyl, (C.sub.2 -C.sub.8) alkenyl, (C.sub.2 -C.sub.8)alkynyl, (C.sub.1 -C.sub.12)alkoxy(C.sub.1 -C.sub.12)alkyl, (C.sub.3 -C.sub.7) cycloalkyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl, aralkyl, and heterocyclic;R.sub.1 and R.sub.2 are independently selected from hydrogen, (C.sub.1 -C.sub.6)alkyl, halo(C.sub.1 -C.sub.
Type:
Grant
Filed:
June 2, 1997
Date of Patent:
March 16, 1999
Assignee:
Rohm and Haas Company
Inventors:
Ronald Ross, Ted Tsutomu Fujimoto, Steven Howard Shaber
Abstract: A compound of the formula ##STR1## wherein R is a) phenyl; phenyl(C.sub.1 -C.sub.4 alkoxy); phenoxy; or benzyl; the phenyl ring of each substituent being optionally substituted with one or more of halogen, nitro, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.8 haloalkyl, C.sub.1 -C.sub.8 haloalkoxy, di(C.sub.1 -C.sub.8 alkyl)amino, phenyl or phenoxy; or b) a 5- or 6-membered heterocyclic group comprising 1-3 heteroatoms selected from the group consisting of N, O or S, optionally substituted with one or more of halogen, nitro, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.8 haloalkyl, C.sub.1 -C.sub.8 haloalkoxy, or di-(C.sub.1 -C.sub.8 alkyl)amino. These compounds and pesticidal compositions prepared therefrom, are useful as plant protecting agents for the control of insects, nematodes, and mites.
Type:
Grant
Filed:
August 21, 1997
Date of Patent:
February 16, 1999
Assignee:
Uniroyal Chemical Company, Inc.
Inventors:
Mark Achiel Dekeyser, Paul Thomas McDonald
Abstract: HIV protease inhibitors, obtainable by chemical synthesis, block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and possibly other anti-viral agents as ingredients, are thus suitable for the treatment of the HIV virus known to cause AIDS.
Type:
Grant
Filed:
October 27, 1994
Date of Patent:
January 26, 1999
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Siegfried H. Reich, Kathleen Lewis, Michael Melnick, Mary Ann M. Fuhry, Stephen Warren Kaldor
Abstract: In accordance with the present invention, there provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 22, 1998
Assignee:
SIBIA Neurosciences, Inc.
Inventors:
Nicholas D. Cosford, Jean-Michel Vernier
Abstract: This invention relates to a key intermediate in the synthesis of an endothelin antagonist and the synthesis of this key intermediate using an asymmetric conjugate addition reaction.
Type:
Grant
Filed:
August 4, 1997
Date of Patent:
December 15, 1998
Assignee:
Merck & Co., Inc.
Inventors:
Ulf H. Dolling, Lisa F. Frey, Richard D. Tillyer, David M. Tschaen
Abstract: This invention relates to substituted and unsubstituted ???(aryl- and heteroaryl-) alkyl-, alkyloxy-, alkylthio-, oxo-, thio-, and alkylamino!- heteroaryl and aryl!- alkylamino-, aminoalkyl-, alkyloxy-, and alkylthio!- aryl and heteroaryl compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, which are useful as antagonists of the pain enhancing effects of E-type prostaglandins, to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods for treating pain comprising the administration of such compounds.
Type:
Grant
Filed:
July 2, 1996
Date of Patent:
November 10, 1998
Assignee:
Zeneca Limited
Inventors:
Gloria Anne Breault, John Oldfield, Howard Tucker, Peter Warner
Abstract: The present invention provides processes for making compounds of the structure(Q--L.sup.1)--L--(L.sup.2 --B)wherein(I) Q is a quinolone moiety;(II) B is a lactam moiety; and(III) L, L.sup.1, and L.sup.2 together comprise a linking moiety;comprising the steps of:(1) coupling a compound of Formula (III) with a lactam-containing compound to form an intermediate compound; and(2) cyclizing the intermediate by reaction with an organosilicon compound to give a compound of the formula (Q--L.sup.1)--L--(L.sup.2 --B).Preferably, the process additionally comprises a step prior to the coupling step, wherein protected forms of the compound of Formula (III) and the lactam compound are formed; and deprotection steps after the cyclization step, wherein the protecting groups are removed. Preferred antimicrobial compounds made by these processes are those where the beta-lactam moiety is a penem, a carbapenem, a cephem, or a carbacephem. Also preferred are those compounds where L.sup.1, L, and L.sup.
Type:
Grant
Filed:
November 12, 1997
Date of Patent:
September 1, 1998
Assignee:
The Procter & Gamble Company
Inventors:
Jared Lynn Randall, Jane Ellen Godlewski
Abstract: Substituted pyridines of the general formula: ##STR1## wherein R.sup.1 is hydroxyl or chlorine, and a) X is hydrogen or chlorine, R.sup.2 and R.sup.3 together are .dbd.O, R.sup.4 is a group of the formula --OR.sup.5 and R.sup.5 is hydrogen, C.sub.1 -C.sub.4 -alkyl or benzyl, orb) X is hydrogen and R.sup.2, R.sup.3 and R.sup.4 together are .dbd.N--NH--, orc) X and R.sup.2 each is hydrogen and R.sup.3 and R.sup.4 together are --O--, ord) X and R.sup.2 each is hydrogen, R.sup.3 is hydroxyl and R.sup.4 is amino or hydroxyl.The compounds are obtained by subjecting nicotine to microbiological oxidation to give 5-succinoyl-2-pyridone, followed by chemical reactions. The compounds are suitable as intermediates for the preparation of pharmaceutically active compounds.
Type:
Grant
Filed:
November 21, 1995
Date of Patent:
June 2, 1998
Assignee:
Lonza, Ltd.
Inventors:
Andreas Kiener, Jean-Paul Roduit, Alain Wellig
Abstract: This invention relates to certain novel benzoxazinone compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
Type:
Grant
Filed:
February 27, 1997
Date of Patent:
May 26, 1998
Assignee:
Merck & Co., Inc.
Inventors:
Ian M. Bell, Roger M. Freidinger, Peter D. Williams
Abstract: There are provided new alkane and alkoxyalkane derivatives of the general formula I
in which R1, R2, R3, R4 and A have the meanings given in the description, processes for their preparation and insecticidal and acaricidal compositions containing these compounds.
Type:
Grant
Filed:
June 20, 1991
Date of Patent:
March 6, 2001
Assignee:
Schering Aktiengesellschaft
Inventors:
Helga Franke, Heinrich Franke, Hans-Rudolf Kruger, Hartmut Joppien, Dietrich Baumert, David Giles